The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Badalyan K.R.

Pirogov Russian National Research Medical University

Painless

Authors:

Badalyan K.R.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2026;(3): 70‑85

Read: 224 times

Contact the author
Table of contents

To cite this article:

Badalyan KR. Painless. Non Nocere. New Therapeutic Journal. 2026;(3):70‑85. (In Russ.)

 
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

Chronic migraine: current concepts and clinical solutions.

Authors:

Badalyan K.R.

Pirogov Russian National Research Medical University

Close metadata

References:

  1. Grangeon L, Lange KS, Waliszewska-Prosół M, et al. Genetics of migraine: where are we now? J Headache Pain. 2023 Feb 20;24(1):12.  https://doi.org/10.1186/s10194-023-01547-8
  2. Hautakangas H, Winsvold BS, Ruotsalainen SE, et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nat Genet. 2022 Feb;54(2):152-160.  https://doi.org/10.1038/s41588-021-00990-0
  3. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018 Feb;17(2):174-182.  https://doi.org/10.1016/S1474-4422(17)30435-0
  4. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017 Apr;97(2):553-622.  https://doi.org/10.1152/physrev.00034.2015
  5. Lipton RB, Buse DC, Nahas SJ, et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023 Dec;270(12):5692-5710. https://doi.org/10.1007/s00415-023-11880-2
  6. Sutherland HG, Jenkins B, Griffiths LR. Genetics of migraine: complexity, implications, and potential clinical applications. Lancet Neurol. 2024 Apr;23(4):429-446.  https://doi.org/10.1016/S1474-4422(24)00026-7
  7. Yeh PK, An YC, Hung KS, Yang FC. Influences of Genetic and Environmental Factors on Chronic Migraine: A Narrative Review. Curr Pain Headache Rep. 2024 Apr;28(4):169-180.  https://doi.org/10.1007/s11916-024-01228-4
  8. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022 Jun 11;23(1):67.  https://doi.org/10.1186/s10194-022-01431-x
  9. Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020 Apr;40(5):503-516.  https://doi.org/10.1177/0333102419883355
  10. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-514.  https://doi.org/10.1038/s41582-021-00509-5
  11. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211.  https://doi.org/10.1177/0333102417738202
  12. Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2019 Jan 15;92(3):134-144.  https://doi.org/10.1212/WNL.0000000000006697
  13. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003 Aug 12;61(3):375-382.  https://doi.org/10.1212/01.wnl.0000078940.53438.83
  14. Fischer MA, Jan A. Medication-Overuse Headache. 2023 Aug 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
  15. Krymchantowski A, Jevoux C, Krymchantowski AG, Ramos LB, Barbosa JSS, Silva-Neto RP. Medication-overuse headache – a review of different treatment strategies. Front Pain Res (Lausanne). 2023 Oct 10;4:1103497. https://doi.org/10.3389/fpain.2023.1103497
  16. Soskin V.M., Naprienko M.V. Chronic migraine and cervicalgia (literature review). Resort medicine. 2024;2:156-163.  https://doi.org/10.24412/2304–0343–2024_2_156
  17. Torres-FerrÚs M, Ursitti F, Alpuente A, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain. 2020 Apr 29;21(1):42.  https://doi.org/10.1186/s10194-020-01111-8
  18. Mungoven TJ, Henderson LA, Meylakh N. Chronic migraine pathophysiology and treatment: a review of current perspectives. Front Pain Res (Lausanne). 2021 Aug 25;2:705276. https://doi.org/10.3389/fpain.2021.705276
  19. Naghdi S, Underwood M, Madan J, et al. Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. J Headache Pain. 2023 Dec 6;24(1):164.  https://doi.org/10.1186/s10194-023-01696-w
  20. Migraine: rubricator of clinical recommendations / Ministry of Health of the Russian Federation. – Electron. Dan. – 2024. – ID: 295_4 (date of access: 01/15/2026). https://cr.minzdrav.gov.ru/view-cr/295_4
  21. Artemenko A.R., Kurenkov A.L., Nikitin S.S., Belomestova K.V. Botulinum neurotoxin and chronic migraine: chemodenervation of muscle fibers or modulation of the nociceptive system? Neuromuscular diseases. 2013;3(4):6-12.  https://doi.org/10.17650/2222-8721-2013-0-4-6-12
  22. Artemenko AR, Abramov VG, Bozhenkina TV, et al. Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):64-74. (In Russ.) https://doi.org/10.17116/jnevro202312311164
  23. https://doi.org/10.20340/vmi-rvz.2023.2.CLIN.2 
  24. Shevchenko V.S., Artemenko A.R., Kurenkov A.L., Bzhilyansky M.A., Bushkov F.A. Assessment of cortical excitability in patients with chronic migraine during treatment with botulinum toxin type A. Russian Journal of Pain. 2018;4:55-60.  https://doi.org/10.25731/RASP.2018.04.028
  25. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010 Jul;30(7):793-803.  https://doi.org/10.1177/0333102410364676
  26. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010 Jul;30(7):804-814.  https://doi.org/10.1177/0333102410364677
  27. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921-936.  https://doi.org/10.1111/j.1526-4610.2010.01678.x
  28. Azimova YuE, Skorobogatykh KV, Korobkova DZ, et al. Experience of Relatox (botulinum toxin type A) using for chronic migraine treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12):134-140. (In Russ.) https://doi.org/10.17116/jnevro2025125121134
  29. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010 Oct;50(9):1406-1418. https://doi.org/10.1111/j.1526-4610.2010.01766.x
  30. Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018 Sep 26;19(1):91.  https://doi.org/10.1186/s10194-018-0921-8
  31. Vashchenko N.V., Korobkova D.Z., Skorobogatikh K.V., Azimova Yu.E. Clinical efficacy and safety of anti-CGRP(r) monoclonal antibodies in real clinical practice after three months of therapy. Neurology, neuropsychiatry, psychosomatics. 2021;13(6):62-66.  https://doi.org/10.14412/2074-2711-2021-6-62-6631
  32. National Institute for Health and Care Excellence. Atogepant for migraine prevention (TA973) [Electronic resource]: final recommendation / NICE. – London, 2024 (date of access: 01/12/2026). https://www.nice.org.uk/guidance/ta973
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.